Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Rectal Neoplasms 2Anus Neoplasms 2Uterine Cervical Neoplasms 1Neoplasms 1HIV Infections 1Benign Colorectal Neoplasm 1Anal Canal Carcinoma 1Adenocarcinoma 1

Interventions

Fluorouracil 267Oxaliplatin 266Capecitabine 224Leucovorin 209Irinotecan 151Radiotherapy 131Bevacizumab 112Cetuximab 81Folfox protocol 48Surgical Procedures, Operative 44Radiation 41Drug Therapy 41Neoadjuvant Therapy 40Chemoradiotherapy 33Chemotherapy, Adjuvant 32Panitumumab 27XELOX 25Magnetic Resonance Spectroscopy 22Radiotherapy, Intensity-Modulated 21Floxuridine 17Biopsy 16Nivolumab 15Gemcitabine 15Early Intervention, Educational 15pembrolizumab 14Laparoscopy 14IFL protocol 14Celecoxib 14trifluridine tipiracil drug combination 13Gene Expression Profiling 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Rectal Neoplasms × Proctoscopy × Clear all
NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

NCT01887509 2018-05-15

TRaMA

IHU Strasbourg

Phase NA Terminated
21 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡